Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates
Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers
Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP 2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions
Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates
Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates
Article content
Article content
VANCOUVER — DCx Biotherapeutics Corporation ('DCx') today announced an agreement with Repare Therapeutics Inc. ('Repare') (NASDAQ: RPTX) to (i) in-license Repare's discovery platform including certain program intellectual property, (ii) retain talent, (iii) acquire lease rights to laboratory facilities in Montreal and (iv) acquire laboratory equipment (the 'Transaction'). Combining the founding team's deep expertise in biologics innovation and development with the newly acquired discovery and translational capabilities, DCx is uniquely positioned to develop a new class of Multi-Modal Antibody Drug Conjugates ('MM-ADCs') against genetically-defined cancers.
Article content
DCx Strategy:
Article content
DCx addresses the root drivers of cancer, genetic mutations that lead to tumor proliferation and survival, by deconvoluting key cellular interdependencies using the MuSic™ platform. Understanding this roadmap enables the mutation-specific drugging of multiple critical targets to synergistically destroy tumors and induce long-term immune memory to achieve durable therapeutic responses while limiting side effects. Unlike current ADCs that deliver broadly chemotoxic payloads to a limited set of antibody targets, DCx's starting strategy is to develop MM-ADCs that optimize the synergy between, and simultaneously target, genetically-defined intracellular and cell-surface targets. The goals for this approach are to (i) increase efficacy, (ii) prolong activity by eliminating escape mechanisms and engaging the immune system, and (iii) improve tolerability while reducing side effects.
Article content
'DCx's founding vision is to realize the full potential of antibody drug conjugates by improving on the selectivity, potency, and tolerability for this promising class of therapeutics thus leading to improved clinical outcomes such as progression-free survival and overall survival,' said Ali Tehrani, PhD, Chief Executive Officer of DCx. 'This transaction with Repare is highly synergistic with our expertise and ambitions and accelerates the development of multiple development candidates over the next three years. We are also looking forward to embarking on this journey together with Repare's world-class preclinical research team that is joining the DCx family.'
Article content
Transaction:
Article content
DCx acquires rights to Repare's proprietary CRISPR, bioinformatics, and machine learning enabled platforms (now known collectively as the MuSic™ Platform) for the identification of surfaceome targets specific to genetic lesions in tumors
DCx obtains non-exclusive license to SNIPRx® and STEP 2 in support of discovering synthetic lethal and other targets
DCx acquires undisclosed surfaceome targets ('Acquired Targets') and antibodies discovered by Repare
DCx acquires undisclosed small molecule programs from Repare
DCx welcomes ~20 scientific and support colleagues spanning expertise in medicinal chemistry, molecular biology, bioinformatics, analytics, and pharmacology
DCx acquires lease rights to certain of Repare's Montreal laboratory facility and certain laboratory equipment
Article content
'We are excited with the potential in what DCx can bring to develop next-gen antibody drug conjugates and how this Transaction, together with a world-class management and scientific team, can meaningful propel these efforts forward,' comments Jean-François Pariseau, DCx Board Chair and Partner at Amplitude Ventures.
Article content
Launched out of Amplitude by Partner Ali Tehrani, DCx is the sixth company launched by Amplitude via its innovation platform. As part of this Transaction, Dr. Tehrani will assume the role of CEO. Other co-founders include Drs. David Poon and Ismael Samudio, and Ms. Candice Madalena. Together, they will leverage their deep experience in drug development, including most recently at Abdera and Zymeworks, which recently had the world's first bi-paratopic antibody therapeutic, Ziihera® (zanidatamab), approved by the FDA.
Article content
The Transaction is effective as of May 1, 2025. In consideration for the Transaction, Repare is eligible to receive, from DCX, the following:
Article content
Upfront and near-term cash payments, together with equity in DCx and a nominee to DCx's board of directors
Out-licensing, clinical, and commercial milestones, as well as low single-digit tiered sales royalties for products developed with Acquired Programs
Out-licensing, clinical, and commercial milestones for products developed with Acquired Targets
Article content
Other financial information is not disclosed.
Article content
DCx Biotherapeutics is a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions by developing multi-modal synergistic-targeting therapeutics with improved efficacy and tolerability while minimizing resistance. DCx's MuSic™ platform is enabled through the integration of CRISPR-based high-throughput functional screening combined with deep bioinformatics in support of advancing a pipeline of immune-stimulatory precision antibody drug conjugates to improve therapeutic outcomes against genetically-defined cancers. Visit www.dcxbio.com to learn more.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
9 minutes ago
- Globe and Mail
Nordson Electronics Solutions to Exhibit High-Yield Fluid Dispensing Technologies for Panel-Level and Wafer-Level Packaging at SEMICON Taiwan 2025
Nordson Electronics Solutions, a global leader in reliable electronics manufacturing technologies, will demonstrate their latest equipment for semiconductor manufacturing at SEMICON Taiwan 2025, September 10-12, booth i2326. This press release features multimedia. View the full release here: Nordson Electronics Solutions continues to develop fluid dispensing systems to meet the challenges of semiconductor advanced packaging that ensure high-throughput, precise fluid dispensing results. The ASYMTEK Vantage system offers several new and innovative configurations to meet the demands of today's evolving technologies, like panel-level packaging. The Vantage system is already a popular dispenser in wafer-level packaging operations including high-volume underfill, dispense gap fill, and sealing lines for fan-out/fan-in, strips, and module assembly. On display will be the ASYMTEK ® Vantage ® dispensing system , configured with two ASYMTEK IntelliJet ® jet valves for high productivity and accuracy for semiconductor packaging and microelectronics manufacturing. The Vantage system offers several new and innovative configurations to meet the demands of today's evolving technologies, like panel-level packaging, The Vantage system is already a popular dispenser in wafer-level packaging operations, including high-volume underfill, dispense gap fill, and sealing lines for fan-out/fan-in, strips, and module assembly. Plasma treatment removes impurities and activates surfaces to enhance flow and adhesion for improved semiconductor package reliability. Nordson experts in plasma treatment will be available to discuss how customers can use this technology for successful advanced packaging operations. The theme for SEMICON Taiwan 2025, 'Leading with Collaboration. Innovating with the World,' will showcase how the semiconductor community is navigating supply chain shifts and how the industry is developing solutions for today and the future. About Nordson Electronics Solutions Nordson Electronics Solutions makes reliable electronics a reality. Through our ASYMTEK, MARCH, and SELECT brands, we supply the world's semiconductor, electronics, and precision assembly manufacturers with the innovative fluid dispensing, conformal coating, plasma treatment, and selective soldering solutions their products need to protect sensitive electronics and deliver a lifespan of reliability. Day after day, year after year, across the globe, for over 40 years, we've provided engineering and applications excellence to help our customers succeed. About Nordson Corporation Nordson Corporation (NASDAQ: NDSN) is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company's direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end-market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at
Globe and Mail
3 hours ago
- Globe and Mail
1 Brilliant Artificial Intelligence (AI) Stock That Will Be Worth More Than Apple by 2030
Key Points AWS and advertising drive Amazon's growth. Apple hasn't released an innovative product or feature in some time. 10 stocks we like better than Amazon › Apple is the world's third-largest company by a wide margin, with a $1 trillion gap between it and fourth-place Alphabet . However, I think several companies are slated to pass Apple in market share over the next five years, including fifth-place Amazon (NASDAQ: AMZN), which is valued at around $2.4 trillion compared to Apple's $3.5 trillion. That's a wide gap to make up in five years, but looking at Amazon's growth tailwinds versus Apple's makes it fairly clear that Amazon is the much better stock pick. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Amazon has two business units driving profit growth Apple's business is fairly straightforward; it's the leading consumer tech brand and generates significant revenue selling iPhones and other products in the Apple ecosystem. Amazon is a bit more complex, as it has the online store that most investors are familiar with, but that's not the best reason to invest in it. Although its online stores division posted the best quarter in a long time (revenue rose 11% year over year), the real stars of the show are Amazon Web Services (AWS) and its advertising services division. AWS is Amazon's cloud computing platform, and it is seeing strong demand fueled by the migration of traditional workloads to the cloud, as well as by new artificial intelligence (AI) workloads. AWS grew revenue by 17% year over year in Q2, which is strong growth considering it generated nearly $31 billion in revenue during the quarter. However, AWS's primary competitors (Microsoft 's Azure and Google Cloud) posted stronger growth rates in their corresponding quarters, so investors are worried about AWS's long-term ability to perform in this sector despite its being the market-share leader. AWS will likely continue to underperform its peers due to its size, but 17% growth is nothing to sneer at. AWS is also a large part of Amazon's profit picture. In Q2, it accounted for 53% of Amazon's operating profits despite accounting for only 18% of revenue. Analysts still expect cloud computing to grow rapidly over the next few years, and if Amazon surpasses Apple in market cap, this will be a primary reason why. Advertising services is Amazon's fastest-growing segment, with revenue rising 23% year over year, an acceleration over previous quarters' growth rate. Amazon has one of the most lucrative places to advertise on the internet, as consumers are already coming to their platform to make purchases. Paying to place a product at the top of an Amazon search almost guarantees increased sales. This is worth a lot to its advertising clients and will be a key part of Amazon's investment thesis over the next few years. Amazon's margins are rising Amazon isn't a revenue growth story; it's a profit growth story. The rise of high-margin businesses like AWS and advertising services has helped Amazon boost its profit margins over the past few years. AMZN Profit Margin data by YCharts With its two high-margin business segments growing faster than other parts of its business, Amazon will naturally have elevated profit growth rates. In Q2, Amazon's operating income rose 31% year over year. Contrast that with Apple, whose Q3 FY 2025 (ending June 28) operating income increased by 11%. Amazon's profit growth rate is much faster. Over five years, a 30% growth rate will increase its operating income by 271% while an 11% growth rate increases operating income by only 69%. That would be enough to drive Amazon's profits higher than Apple's, propelling it to surpass it in size along the way. Amazon is an excellent stock pick for the next five years and a no-brainer buy at today's prices. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Keithen Drury has positions in Alphabet and Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
10 hours ago
- Globe and Mail
BWEN Investors Have Opportunity to Join Broadwind, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Broadwind, Inc. ('Broadwind' or 'the Company') (NASDAQ: BWEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Broadwind announced its Q2 2025 financial results on August 12, 2025. The Company missed consensus estimates for earnings per share, and suspended its full-year 2025 guidance. Based on this news, shares of Broadwind fell by more than 14.4% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
